These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 2326574)

  • 21. Prognostic value of cathepsin-D expression in female breast cancer.
    Aaltonen M; Lipponen P; Kosma VM; Aaltomaa S; Syrjänen K
    Anticancer Res; 1995; 15(3):1033-7. PubMed ID: 7645922
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Modelling the effects of standard prognostic factors in node-positive breast cancer. German Breast Cancer Study Group (GBSG).
    Sauerbrei W; Royston P; Bojar H; Schmoor C; Schumacher M
    Br J Cancer; 1999 Apr; 79(11-12):1752-60. PubMed ID: 10206288
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Expression of prostate-specific antigen (PSA) correlates with poor response to tamoxifen therapy in recurrent breast cancer.
    Foekens JA; Diamandis EP; Yu H; Look MP; Meijer-van Gelder ME; van Putten WL; Klijn JG
    Br J Cancer; 1999 Feb; 79(5-6):888-94. PubMed ID: 10070886
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pathological parameters useful in predicting prognosis for patients with breast cancer.
    Hutter RV
    Monogr Pathol; 1984; (25):175-85. PubMed ID: 6377048
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Contraception without risk of breast disease: epidemiologic and physiopathologic arguments].
    Le Coutour X
    NPN Med; 1985 Apr; 5(88):471-6. PubMed ID: 12315304
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The prognostic significance of the percentage of positive/dissected axillary lymph nodes in breast cancer recurrence and survival in patients with one to three positive axillary lymph nodes.
    Truong PT; Berthelet E; Lee J; Kader HA; Olivotto IA
    Cancer; 2005 May; 103(10):2006-14. PubMed ID: 15812825
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tumour markers CEA and CA 15-3 as Prognostic factors in breast cancer--univariate and multivariate analysis.
    Ebeling FC; Schmitt UM; Untch M; Nagel D; Fateh-Moghadam A; Stieber P; Seidel D
    Anticancer Res; 1999; 19(4A):2545-50. PubMed ID: 10470192
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prediction of survival in breast cancer. Principles and current status of hormone receptors and DNA content as prognostic factors.
    Adami HO; Killander D
    Acta Chir Scand Suppl; 1984; 519():25-34. PubMed ID: 6595924
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Breast cancer risk with postmenopausal hormonal treatment.
    Collins JA; Blake JM; Crosignani PG
    Hum Reprod Update; 2005; 11(6):545-60. PubMed ID: 16150813
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adjuvant therapy for breast cancer.
    NIH Consens Statement; 2000 Nov 1-3; 17(4):1-35. PubMed ID: 11512506
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Breast cancer in women aged 35 and under: prognosis and survival.
    Jmor S; Al-Sayer H; Heys SD; Payne S; Miller I; Ah-See A; Hutcheon A; Eremin O
    J R Coll Surg Edinb; 2002 Oct; 47(5):693-9. PubMed ID: 12463710
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A high number of tumor free axillary lymph nodes from patients with lymph node negative breast carcinoma is associated with poor outcome.
    Camp RL; Rimm EB; Rimm DL
    Cancer; 2000 Jan; 88(1):108-13. PubMed ID: 10618612
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Axillary lymph node micrometastases in invasive breast cancer: national figures on incidence and overall survival.
    Grabau D; Jensen MB; Rank F; Blichert-Toft M
    APMIS; 2007 Jul; 115(7):828-37. PubMed ID: 17614850
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Local recurrence after mastectomy for breast cancer: analysis of clinicopathological, biological and prognostic characteristics.
    Carreño G; Del Casar JM; Corte MD; González LO; Bongera M; Merino AM; Juan G; Obregón R; Martínez E; Vizoso FJ
    Breast Cancer Res Treat; 2007 Mar; 102(1):61-73. PubMed ID: 16850244
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Interleukin-6 -174G-->C polymorphism is associated with improved outcome in high-risk breast cancer.
    DeMichele A; Martin AM; Mick R; Gor P; Wray L; Klein-Cabral M; Athanasiadis G; Colligan T; Stadtmauer E; Weber B
    Cancer Res; 2003 Nov; 63(22):8051-6. PubMed ID: 14633738
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Relationship of clinical and pathologic response to neoadjuvant chemotherapy and outcome of locally advanced breast cancer.
    Gajdos C; Tartter PI; Estabrook A; Gistrak MA; Jaffer S; Bleiweiss IJ
    J Surg Oncol; 2002 May; 80(1):4-11. PubMed ID: 11967899
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prediction of recurrence for advanced breast cancer. Traditional and contemporary pathologic and molecular markers.
    Masood S
    Surg Oncol Clin N Am; 1995 Oct; 4(4):601-32. PubMed ID: 8535901
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association between extent of axillary lymph node dissection and patient, tumor, surgeon, and hospital factors in patients with early breast cancer.
    Petrik DW; McCready DR; Sawka CA; Goel V
    J Surg Oncol; 2003 Feb; 82(2):84-90. PubMed ID: 12561062
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic significance of periodic acid-Schiff-positive patterns in primary breast cancer and its lymph node metastases.
    Buijs JT; Cleton AM; Smit VT; Löwik CW; E Papapoulos S; Pluijm Gv
    Breast Cancer Res Treat; 2004 Mar; 84(2):117-30. PubMed ID: 14999142
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Serum calcium and tumour aggressiveness in breast cancer: a prospective study of 7847 women.
    Almquist M; Anagnostaki L; Bondeson L; Bondeson AG; Borgquist S; Landberg G; Malina J; Malm J; Manjer J
    Eur J Cancer Prev; 2009 Sep; 18(5):354-60. PubMed ID: 19593149
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.